The DOI matches its Crossref record.
Bad Bugs, No Drugs: No ESCAPE Revisited
Open accessAbstract
To the Editor—It was with appreciation that I read your update from the Infectious Diseases Society of America in the January 2009 issue of the journal that highlighted the impact of the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa , and Enterobacter species) as a group of particularly troublesome bacteria having the ability to “escape” the effects of current antimicrobial agents [1]. I would, however, like to offer a “friendly amendment” and suggest that, moving forward, the term “ESKAPE” be changed to “ESCAPE” (E. faecium, S. aureus, Clostridium difficile, A. baumannii, P. aeruginosa , and Enterobacteriaceae). Including C. difficile as the new “C” acknowledges C. difficile infection (CDI) as one of the problematic diseases, and this inclusion is justified because CDI is one of the most common hospital-associated infections that we face, occurring among patients receiving antibiotics and thus “escaping” the beneficial effects of these antibiotics. Globally, cases of CDI appear to be growing more virulent [2], with CDI causing more frequent illness than in the past [3] and with patients not responding well to metronidazole therapy [4]. This recognition of C. difficile would not only include it in the acronym ESCAPE but would also potentially focus the need for increased funding to understand CDI's unique relationship as a complication in the treatment of modern infectious diseases. As to including Enterobacteriaceae in the ESCAPE pathogens as the new final “E,” this new terminology (ESCAPE) would then encompass not only K. pneumoniae (the former “K”) and Enterobacter species (the former final “E”) but also the other critically important pathogens that can express increasing levels of antibiotic resistance (including extended-spectrum β-lactamases and carbapenemases), aminoglycoside resistance, and decreasing levels of fluoroquinolone susceptibility (namely, Escherichia coli and Proteus species) [5]. I suggest this change because drug resistance in isolates of E .coli, K. pneumoniae, Enterobacter species, and other members of Enterobacteriaceae is not only a potential threat but a reality that needs to be stressed. Even though the percentage of drug-resistant isolates may be lower for E. coli , the fact that E. coli is the predominant etiologic pathogen for gram-negative infections indicates that it represents a greater total burden of disease than do K. pneumonia and Enterobacter species combined [6–7]. Furthermore, Livermore et al [8] point out that E. coli infections currently account for ∼20% of all cases of bacteremia in the United Kingdom. This rivals the incidence of S. aureus infection and is nearly double that associated with any other pathogen. This finding, coupled with the emergence of extended-spectrum β-lactamase-mediated and carbapenemase-mediated resistance in Enterobacteriaceae other than Klebsiella species, speaks to the benefit of focusing on the larger family of Enterobacteriaceae as a global problem in the aggregate burden of infectious diseases. Boucher et al eloquently reiterate that “the late-stage clinical development pipeline for antibacterials remains unacceptably lean” and that “the United States must make the development of a sustainable antibacterial drug research and development infrastructure a national priority” [1, pp. 9-10]. The ESCAPE concept is a most useful idea to focus attention on the problematic bacterial pathogens that we are all now facing in global health care. I suggest a slight change in the spelling of the acronym, thereby having it encompass more fully all of the current problem pathogens that challenge the safe and efficacious treatment of infectious diseases. Potential conflicts of interest. L.R.P.: no conflicts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Developmental dynamics of the preterm infant gut microbiota and antibiotic resistome
Gibson, M. K., Wang, B., Ahmadi, S., Burnham, C.-A. D., Tarr, P. I., Warner, B. B., & Dantas, G. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.24 · Cited by 457
Multidrug Resistant and Extensively Drug Resistant Bacteria: A Study
Basak, S., Singh, P., & Rajurkar, M. (2016) · Journal of Pathogens · doi:10.1155/2016/4065603 · Cited by 395
Infections Caused by Resistant Gram‐Negative Bacteria: Epidemiology and Management
Kaye, K. S., & Pogue, J. M. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1636 · Cited by 383
Cohen, C. R., Lingappa, J. R., Baeten, J. M., Ngayo, M. O., Spiegel, C. A., Hong, T., Donnell, D., Celum, C., Kapiga, S., Delany, S., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001251 · Cited by 374
Metadata
- Authors
- Peterson, L. R.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-09-15
- Volume
- 49
- Issue
- 6
- Pages
- 992-993
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2135922137
- Cited by
- 187
- References
- 0
- FWCI
- 9.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bad Bugs, No Drugs: No ESCAPE Revisited. https://app.cochat.ai/papers/10.1086/605539
- The paper
- Peterson, L. R. (2009). Bad Bugs, No Drugs: No ESCAPE Revisited. Clinical Infectious Diseases. https://doi.org/10.1086/605539
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.